StockData
Neurogene Inc. logo

Neurogene Inc. (NGNE) stock

NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$23.10−0.20 (-0.86%)

Close on Nov 17, 2026Market cap $462.26MP/E –Yield –

Neurogene operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Neurogene's operating cash flow for the twelve months ending Jun 30, 2026 was -$86.82M. For fiscal 2025 it was -$77.17M. The highest annual figure on record is -$7.23M in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$77.17M–
FY2024Dec 31, 2024-$70.60M–
FY2023Dec 31, 2023-$51.42M–
FY2022Dec 31, 2022-$52.82M–
FY2021Dec 31, 2021-$47.56M–
FY2020Dec 31, 2020-$24.58M–
FY2019Dec 31, 2019-$15.39M–
FY2018Dec 31, 2018-$31.58M–
FY2017Dec 31, 2017-$44.72M–
FY2016Dec 31, 2016-$30.23M–
FY2015Dec 31, 2015-$20.27M–
FY2014Dec 31, 2014-$17.49M–
FY2013Dec 31, 2013-$7.82M–
FY2012Dec 31, 2012-$7.23M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$23.76M–
Q1 FY2026Mar 31, 2026-$26.12M–
Q4 FY2025Dec 31, 2025-$17.43M–
Q3 FY2025Sep 30, 2025-$19.51M–
Q2 FY2025Jun 30, 2025-$19.46M–
Q1 FY2025Mar 31, 2025-$20.77M–
Q4 FY2024Dec 31, 2024-$17.50M–
Q3 FY2024Sep 30, 2024-$15.56M–
Q2 FY2024Jun 30, 2024-$15.89M–
Q1 FY2024Mar 31, 2024-$21.65M–
Q4 FY2023Dec 31, 2023-$16.97M–
Q3 FY2023Sep 30, 2023-$11.57M–
Q2 FY2023Jun 30, 2023-$9.33M–
Q1 FY2023Mar 31, 2023-$13.56M–
Q4 FY2022Dec 31, 2022-$18.15M–
Q3 FY2022Sep 30, 2022-$9.29M–
Q2 FY2022Jun 30, 2022-$11.29M–
Q1 FY2022Mar 31, 2022-$14.09M–
Q4 FY2021Dec 31, 2021-$12.17M–
Q3 FY2021Sep 30, 2021-$8.76M–
Q2 FY2021Jun 30, 2021-$13.28M–
Q1 FY2021Mar 31, 2021-$13.36M–
Q4 FY2020Dec 31, 2020-$9.23M–
Q3 FY2020Sep 30, 2020-$112.00K–
Q2 FY2020Jun 30, 2020-$8.79M–
Q1 FY2020Mar 31, 2020-$6.44M–
Q4 FY2019Dec 31, 2019-$4.64M–
Q3 FY2019Sep 30, 2019-$6.53M–
Q2 FY2019Jun 30, 2019-$1.47M-116.0%
Q1 FY2019Mar 31, 2019-$2.76M–
Q4 FY2018Dec 31, 2018-$9.78M–
Q3 FY2018Sep 30, 2018-$15.39M–
Q2 FY2018Jun 30, 2018$9.18M–
Q1 FY2018Mar 31, 2018-$15.59M–
Q4 FY2017Dec 31, 2017-$11.61M–
Q3 FY2017Sep 30, 2017-$11.53M–
Q2 FY2017Jun 30, 2017-$10.30M–
Q1 FY2017Mar 31, 2017-$11.28M–
Q4 FY2016Dec 31, 2016-$9.00M–
Q3 FY2016Sep 30, 2016-$7.44M–

More Neurogene figures

See a number that looks wrong?